This study investigates the roles of RUVBL1 and HIF1A in ccRCC development and explores their clinical significance as prognostic biomarkers. mRNA and protein expressions were analyzed using TCGA data and an institutional tissue cohort, respectively. Correlations with clinicopathological parameters and patient outcomes were assessed. TCGA data revealed significantly elevatedRUVBL1mRNA expression in ccRCC tissues, associated with advanced histological grade, T stage, lymph node metastasis, and clinical stage. HighRUVBL1mRNA expression correlated with inferior overall survival and served as an adverse prognostic factor. Similarly,HIF1AmRNA expression was significantly higher in ccRCC tissues, correlating with worse overall survival and acting as an adverse prognostic factor for treatment outcomes. Simultaneous evaluation ofRUVBL1andHIF1AmRNA expression demonstrated enhanced prognostic capacity, surpassing the predictive power of individual markers. Immunohistochemical staining confirmed substantial upregulation of both RUVBL1 and HIF-1α proteins in ccRCC tissues. Furthermore, high expression of both RUVBL1 and HIF-1α proteins was significantly associated with shorter patient survival time. Our findings underscore the significance of RUVBL1 and HIF-1α as potential prognostic markers in ccRCC, paving the way for further research to translate these insights into clinically relevant applications.
本研究探讨了RUVBL1与HIF1A在透明细胞肾细胞癌（ccRCC）发生发展中的作用，并评估其作为预后生物标志物的临床意义。通过TCGA数据库及机构组织样本队列分别检测mRNA及蛋白表达水平，分析其与临床病理参数及患者预后的相关性。TCGA数据分析显示，ccRCC组织中RUVBL1 mRNA表达显著升高，且与组织学分级、T分期、淋巴结转移及临床分期进展密切相关。高RUVBL1 mRNA表达与患者总生存期缩短显著相关，是不良预后的独立危险因素。同样，HIF1A mRNA在ccRCC组织中表达显著上调，与较差的总生存期相关，是治疗结局的不良预后因子。联合评估RUVBL1与HIF1A mRNA表达可显著提升预后预测效能，其预测能力优于单一标志物。免疫组化染色证实，ccRCC组织中RUVBL1与HIF-1α蛋白均呈现显著高表达。此外，RUVBL1与HIF-1α蛋白双高表达与患者生存时间缩短显著相关。本研究结果揭示了RUVBL1与HIF-1α作为ccRCC潜在预后标志物的重要价值，为后续开展临床转化研究奠定了理论基础。
肿瘤(癌症)患者之家